middle.news
Mesoblast’s Ryoncil Generates US$13.2M in First Quarter Post FDA Launch
10:11am on Friday 18th of July, 2025 AEST
•
Healthcare
Read Story
Mesoblast’s Ryoncil Generates US$13.2M in First Quarter Post FDA Launch
10:11am on Friday 18th of July, 2025 AEST
Key Points
US$13.2 million gross revenue from Ryoncil sales in first quarter post-launch
Onboarding of 25+ transplant centers, targeting 45 priority centers in US
Mandatory Medicaid coverage effective July 1, expanding patient access
Seven years orphan drug exclusivity and biologic exclusivity until 2036 secured
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Mesoblast (ASX:MSB)
OPEN ARTICLE